Allmed Solutions Overview
Allmed Solutions develops, manufactures, and markets minimally invasive products designed to benefit patients by improving and shortening the recovery process. The company's products are used by physicians to treat a wide range of diseases and patients worldwide. Allmed Solutions currently markets three minimally invasive medical device product lines: an embolic protection device, urological and biliary stents, and pelvic organ prolapse repair devices. The company is also developing a gastro-duodenal sleeve for the treatment of type 2 diabetes and a mitral valve replacement. Each of Allmed Solutions' product lines is operated by one its subsidiaries, all of which are located in the company's corporate headquarters and benefit from its collective engineering, operating, regulatory, clinical, and marketing infrastructure to support their respective activities.
Cumulative Funding Raised Over Time ($)
$3.4MSep 2022
Latest News
growth-positive
Middle Eastern Penny Stocks With At Least US$2M Market Cap
Allmed Solutions Ltd, a pre-revenue company with a market cap of ₪30.37 million, is making significant progress in the field of minimally invasive medical products. The companys recent development of the RoseDoc docking system represents a major advancement in heart valve replacement technology, offering a potential alternative to open-heart surgery. Despite reporting a net loss of ₪7 million for the first half of 2025, Allmed Solutions remains stable due to its experienced management and debt-free status. The company has a cash runway exceeding three years, which supports its ongoing development efforts.
Product Stage
growth-positive
Middle Eastern Penny Stock Insights: Ras Al Khaimah for White Cement & Construction Materials P.S.C And 2 More Opportunities
Ras Al Khaimah Co. for White Cement & Construction Materials P.S.C. is highlighted as a promising penny stock investment in the Middle East market. The company is debt-free, which reduces financial risk, and its short-term assets significantly exceed liabilities, providing liquidity stability. Earnings have grown at an average of 15.5% annually over the past five years, although recent growth has slowed to 11.4%, trailing industry averages. Despite trading significantly below estimated fair value and having high-quality earnings, the stock exhibits high volatility and low return on equity at 4.5%. Recent earnings reports show improved sales and net income year-over-year but slight margin contraction.
growth-positive
/PRNewswire/ -- AllMeD Solutions (TASE: ALMD), which holds the Israeli biomedical company TruLeaf-Medical, announced the successful completion of stage 1 of...
TruLeaf-Medical, part of AllMeD Solutions, has successfully completed the first phase of a first-in-human clinical trial for its innovative RoseDoc docking system. This system allows for the transcatheter replacement of tricuspid and mitral heart valves without the need for open-heart surgery. The trial was conducted on two patients in India on September 5th, 2025, using a compassionate care pathway. This marks a significant proof of concept for TruLeafs technology, which aims to provide a less invasive treatment option for patients with defective heart valves. The company plans to continue patient recruitment and expand trial sites to additional countries.
Product StageCustomers
growth-positive
Global Breakthrough: TruLeaf Implanted First-of-its-Kind Heart Valve via Catheter Only, Without Surgery
TruLeaf Medical, part of the AllMeD Solutions group, has successfully completed the first phase of a first-in-human clinical trial for its innovative RoseDoc docking system. This system allows for the transcatheter replacement of tricuspid and mitral heart valves, eliminating the need for open-heart surgery. The procedure was first performed on September 5th, 2025, in India on patients with severe congestive heart failure. This milestone marks a significant proof of concept for TruLeafs technology, which aims to provide a less invasive treatment option for patients with defective heart valves. The company plans to continue patient recruitment and expand trial sites to additional countries, accelerating the process toward regulatory approval.
Product StageCustomers
growth-negative
Middle Eastern Penny Stocks Spotlight: Allmed Solutions And Two Others To Consider
Allmed Solutions Ltd, a company with a market cap of ₪29.12 million, is highlighted in the context of Middle Eastern penny stocks. Despite being pre-revenue and unprofitable with net losses of ₪7 million for the first half of 2025, the company maintains strong liquidity as its short-term assets exceed its liabilities. Allmed Solutions is debt-free and has a stable weekly volatility of 6%. The company has filed a shelf registration for various securities, indicating potential future capital raising. The article discusses the broader context of Middle Eastern markets experiencing a downturn, with penny stocks offering potential growth opportunities.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $3.4M |
| Last funding | $3.4M |
| Stage | Public |
| Rounds | 2 |
| Investors | 1 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | almd-solutions.com |
Locations
HaEshel Street 2, Caesarea, Israel
Photos & Videos
2 item(s)
Allmed Solutions Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Materials & SubstancesPolymersImplantsTags (14)
surgerydiabetesgastroenterologymedical-devicesgynecologyminimally-invasivemedical-productsurologycardiovascularstenthospitalscardiologypolymersdoctorsGeographic Markets
United Arab EmiratesGlobalEgyptAllmed Solutions Financials
$3.4M
Total funding
Undisclosed
Capital raised
$3.4M
Last funding
Public
Funding stage
2
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$3.4MSep 2022
Private Equity Funding
PIPE
Sep 2022
$3.4M
David Milch
Public Offering / Exit
POEvent
Feb 2007
Undisclosed
Allmed Solutions Lifecycle
Cumulative Funding Raised Over Time
$3.4MSep 2022
All Events
PIPE
Sep 2022
$3.4M
David Milch
POEvent
Feb 2007
Undisclosed
Allmed Solutions News
24 articles
growth-positive
Middle Eastern Penny Stocks With At Least US$2M Market Cap
Allmed Solutions Ltd, a pre-revenue company with a market cap of ₪30.37 million, is making significant progress in the field of minimally invasive medical products. The companys recent development of the RoseDoc docking system represents a major advancement in heart valve replacement technology, offering a potential alternative to open-heart surgery. Despite reporting a net loss of ₪7 million for the first half of 2025, Allmed Solutions remains stable due to its experienced management and debt-free status. The company has a cash runway exceeding three years, which supports its ongoing development efforts.
Product Stage
growth-positive
Middle Eastern Penny Stock Insights: Ras Al Khaimah for White Cement & Construction Materials P.S.C And 2 More Opportunities
Ras Al Khaimah Co. for White Cement & Construction Materials P.S.C. is highlighted as a promising penny stock investment in the Middle East market. The company is debt-free, which reduces financial risk, and its short-term assets significantly exceed liabilities, providing liquidity stability. Earnings have grown at an average of 15.5% annually over the past five years, although recent growth has slowed to 11.4%, trailing industry averages. Despite trading significantly below estimated fair value and having high-quality earnings, the stock exhibits high volatility and low return on equity at 4.5%. Recent earnings reports show improved sales and net income year-over-year but slight margin contraction.
growth-positive
/PRNewswire/ -- AllMeD Solutions (TASE: ALMD), which holds the Israeli biomedical company TruLeaf-Medical, announced the successful completion of stage 1 of...
TruLeaf-Medical, part of AllMeD Solutions, has successfully completed the first phase of a first-in-human clinical trial for its innovative RoseDoc docking system. This system allows for the transcatheter replacement of tricuspid and mitral heart valves without the need for open-heart surgery. The trial was conducted on two patients in India on September 5th, 2025, using a compassionate care pathway. This marks a significant proof of concept for TruLeafs technology, which aims to provide a less invasive treatment option for patients with defective heart valves. The company plans to continue patient recruitment and expand trial sites to additional countries.
Product StageCustomers
growth-positive
Global Breakthrough: TruLeaf Implanted First-of-its-Kind Heart Valve via Catheter Only, Without Surgery
TruLeaf Medical, part of the AllMeD Solutions group, has successfully completed the first phase of a first-in-human clinical trial for its innovative RoseDoc docking system. This system allows for the transcatheter replacement of tricuspid and mitral heart valves, eliminating the need for open-heart surgery. The procedure was first performed on September 5th, 2025, in India on patients with severe congestive heart failure. This milestone marks a significant proof of concept for TruLeafs technology, which aims to provide a less invasive treatment option for patients with defective heart valves. The company plans to continue patient recruitment and expand trial sites to additional countries, accelerating the process toward regulatory approval.
Product StageCustomers
growth-negative
Middle Eastern Penny Stocks Spotlight: Allmed Solutions And Two Others To Consider
Allmed Solutions Ltd, a company with a market cap of ₪29.12 million, is highlighted in the context of Middle Eastern penny stocks. Despite being pre-revenue and unprofitable with net losses of ₪7 million for the first half of 2025, the company maintains strong liquidity as its short-term assets exceed its liabilities. Allmed Solutions is debt-free and has a stable weekly volatility of 6%. The company has filed a shelf registration for various securities, indicating potential future capital raising. The article discusses the broader context of Middle Eastern markets experiencing a downturn, with penny stocks offering potential growth opportunities.
growth-negative
Middle Eastern Penny Stocks To Watch In July 2025
Al Wathba National Insurance Company PJSC, operating in the general insurance and reinsurance sectors, has shown resilience despite recent challenges. With a market cap of AED676.89 million, the company reported a net loss of AED16.05 million for Q1 2025, which is an improvement from the previous years loss. The companys financial stability is supported by having more cash than total debt and short-term assets exceeding both short and long-term liabilities. However, profit margins have significantly declined, and earnings growth remains negative compared to industry averages. Dividend payments have been unstable, reflecting ongoing volatility in its financial performance.
growth-positive
Middle Eastern Penny Stocks With Market Caps Under US$900M To Consider
Al Seer Marine Supplies and Equipment Company PJSC, a company involved in yacht management and operations in the UAE, is making strategic moves to strengthen its position in the maritime sector. Despite being currently unprofitable, the company has formed a joint venture with B International Shipping & Logistics to create ASBI Shipping FZCO, securing AED 660 million in revenue through a 10-year charter. The company is addressing regional demand with a production agreement for high-speed interceptor vessels. While facing challenges in profitability and share price volatility, Al Seer Marines short-term assets cover its liabilities, indicating a stable financial position.
Partners
growth-negative
Middle Eastern Penny Stocks: 3 Picks With Market Caps Over US$8M
Al Seer Marine Supplies and Equipment Company PJSC, operating in the yacht management sector in the UAE, faces financial challenges despite substantial revenue from its yachting segment. The company is currently unprofitable, with earnings declining by 51.1% annually over five years. Its net debt to equity ratio is satisfactory at 36.4%, but debt coverage by operating cash flow is weak at 6.3%. Short-term assets cover liabilities, but share price volatility remains high, reflecting investor caution amidst financial challenges and management uncertainties.
growth-positive
Middle Eastern Market Movers: Hily Holding PJSC Among 3 Penny Stocks To Consider
Hily Holding PJSC, a company managing securities portfolios across the UAE, Saudi Arabia, Kuwait, and Bahrain, has demonstrated significant financial growth. The companys revenue increased from AED70.48 million to AED110.99 million, and net income rose from AED6.53 million to AED25.15 million. Despite a low return on equity and negative operating cash flow affecting debt coverage, the companys net debt to equity ratio remains satisfactory. Hilys earnings growth of 285.4% over the past year surpasses industry averages, although interest payments are poorly covered by EBIT. The article highlights the companys improved profit margins and reduced debt levels over five years.
growth-negative
Middle Eastern Market Gems: Al Dhafra Insurance Company P.S.C Among 3 Promising Penny Stocks
Al Dhafra Insurance Company P.S.C., operating in the insurance and reinsurance sectors across the UAE and internationally, is experiencing financial challenges despite maintaining high-quality earnings and a stable financial health rating. The company has a market cap of AED 486 million and operates without debt, appealing to risk-averse investors. However, recent earnings have declined from AED 41.3 million to AED 38.38 million, and profit margins have reduced, indicating challenges in maintaining profitability amidst industry pressures. The company has proposed a cash dividend of AED 35 million, demonstrating a commitment to returning value to shareholders. The article highlights the broader context of Middle Eastern stock markets experiencing a downturn due to geopolitical concerns and U.S. tariffs.
growth-positive
Vote of confidence in TruLeaf Medical, subsidiary of AllMeD Solutions: 11.5 million NIS grant awarded by the Israel Innovation Authority
TruLeaf Medical, a subsidiary of AllMeD Solutions, has received a grant of approximately $410,000 from the Israel Innovation Authority. This is the sixth time the company has received the grant, bringing the total to approximately $3.14 million. The grant was approved after a comprehensive evaluation by the Innovation Authority. TruLeaf has developed a unique platform, RoseDoc, that can replace a diseased heart valve through catheterization alone. This minimally invasive procedure will significantly reduce the risk associated with valve replacement involving open-heart surgery. The grant comes several weeks after TruLeaf received approval to conduct clinical trials on humans in Uzbekistan.
Investment
growth-positive
A New Era in Heart Surgery - Israeli Biomed Company TruLeaf Medical's Two Needle Sticks Procedure for Mitral Valve Replacement
AllMeD Solutions subsidiary, TruLeaf Medical, has received approval from the Helsinki Ethics Committee in Uzbekistan to conduct a clinical trial in human subjects. The trial will test a minimally invasive heart valve treatment, which involves implanting a prosthetic mitral valve via two needle sticks in the groins, eliminating the need for open-heart surgery. The procedure, developed by TruLeaf, could potentially benefit millions of patients worldwide suffering from severe, life-threatening mitral valve regurgitation. The approval paves the way for human implantations in clinical trials in Uzbekistan.
CustomersExpand
growth-positive
AllMeD Solutions פורצת דרך: הליכים זעיר פולשניים במקום ניתוחים
AllMeD Solutions, an Israeli holding company, is developing innovative solutions for medical problems through its two medical start-ups. Allevetix Medical is working on a solution for type 2 diabetes and obesity, aiming to achieve the benefits of gastric bypass surgery without the surgery itself. TruLeaf Medical is developing a solution for mitral valve leakage, a common heart condition. Both companies have successfully completed animal trials and are awaiting approval for human trials.
InvestmentExpand
growth-positive
It Might Be the End of Open-Heart Surgeries: Israeli Biomed Company TruLeaf Medical Will Implant a Mitral Heart Valve via Two Needle Sticks only in a Two-Stage Catheterization Without Surgery
AllMeD Solutions announced that its subsidiary, TruLeaf Medical, has received approval from the Helsinki Ethics Committee to conduct a clinical trial in human subjects. The trial will involve the implantation of a prosthetic mitral valve via a two-stage catheterization procedure, eliminating the need for open-heart surgery. The procedure uses the RoseDoc platform developed by TruLeaf, which replaces the patients leaky heart valve. The mitral valve market is estimated to be worth about $15 billion a year in the U.S. alone. TruLeaf Medical was founded in 2017 by three Israeli entrepreneurs.
CustomersExpand
growth-positive
AllMeD Solutions Reports Receipt of the Full Payment for PIPE Fundraising of Over $3.5 Million
AllMeD Solutions has announced the receipt of full consideration for the last round of PIPE fundraising, amounting to over $3.5 million. The fundraising was at a premium of 45% above the market share price prior to approval of the transaction by the board of directors. This comes at a challenging time for the field of Bio-Med, as well as for public companies in general. AllMeD has been undergoing many changes recently since the appointment of the new company CEO, Professor Oz Shapira. The company has raised $47 million since it was founded and recently sold two subsidiaries for a total sum of $23 million.
InvestmentManagement Changes
growth-positive
אולמד מוכרת את חברת הבת אליום ב-20 מיליון ש"ח
אולמד סולושנס, a company specializing in medical technologies, has announced the sale of its subsidiary, Elium, which focuses on the production and marketing of peripheral stents. The sale will be made to the companys distributor in Germany for a total of 20 million shekels and 50% of Eliums net profit if sales exceed $12.8 million over a three-year period starting in August 2021. The sale is part of the companys plan to focus on its innovative core activities and explore other strategic transactions. The CEO of אולמד סולושנס stated that the proceeds from the sale will provide operational flexibility and opportunities for strategic and business development.
Acquisition
אולמד סולושנס מעריכה צמיחה של כ-28% במכירות החברה ברבעון הראשון 2021
growth-positive
אליום מדיקל חתמה על הסכם הפצה באיחוד האמירויות ובמצרים
Elum Medical, a medical technology company specializing in nanotechnology, has signed a distribution agreement for the marketing and distribution of urological stents. The exclusive agreement, with a distributor experienced in marketing medical equipment, will allow Elum Medical to expand into new markets and create new growth opportunities. The agreement covers the United Arab Emirates and Egypt, with plans to enter other Arab markets. The regulatory approval process is expected to be completed in the first quarter of 2021. Elum Medicals stents have marketing approvals in Europe, China, South Africa, Australia, India, and Israel, and the company is working to obtain additional approvals in China and other countries.
Partners
growth-positive
Allium Medical sells embolic protection system for $17m
Cardiovascular Systems is acquiring the WIRION Embolic Protection System and related assets from Allium Medical Solutions for $17 million. The WIRION System is a distal embolic protection filter used in peripheral vascular intervention procedures. It is easier to use and more versatile than other available systems. Cardiovascular Systems plans to commercialize the WIRION System in the US after a manufacturing transfer from Gardia Medical. The transfer is expected to be completed in 12-15 months. Gardia will retain the rights to the WIRION System for carotid artery procedures.
Acquisition
growth-positive
Allium Medical Receives CFDA Clearance to Market its Minimally-invasive BPH Implant and Premium Urological Stents in China
Allium Medical, an Israeli medical device company, has received regulatory clearance from the China Food and Drug Administration (CFDA) to market its portfolio of urological systems in China. The company has an exclusive strategic agreement with a leading distribution organization in Chinas urology market and expects to generate significant revenue in 2018. The urological implants are designed to treat ureteral and urethra obstructions, and the procedure for insertion is minimally invasive. Allium Medical sees the CFDA clearance as an important milestone in growing its business in the Asia-Pacific region.
Customers
growth-positive
Allium Medical wins Chinese marketing urological stent nod
Allium Medical Ltd. has obtained marketing approval for its urological stent in China, leading to a 12.5% increase in share price. A Chinese company will order NIS 88 million worth of products from Allium Medical over eight years. The company also obtained marketing approval in Russia for its gynecological product. Allium Medicals revenue from its urological and gynecological products has been growing slowly but steadily. The company has consistently lost money due to investments in more complex products. Allium Medical is looking for a strategic partner or buyer for its device for preventing embolisms. The company has added two more products to its portfolio. As of the end of 2017, Allium Medical had NIS 22 million in cash.
Customers
growth-positive
Allium Medical: Gardia Successfully met all Clinical Study Endpoints set by the FDA, at the Interim Stage of Recruiting Half the Number of Patients Defined in the Study Protocol
Allium Medical, an Israeli medical devices company, announced that the FDA confirmed the successful achievement of all clinical study objectives for their product Gardia. This milestone brings them closer to obtaining FDA approval. The company plans to submit a full response to the FDA in the next two months. The Gardia WIRION system has received positive feedback from European physicians and has competitive advantages over other FDA cleared products. The market for the Gardia product is estimated at $550 million per year. Allium Medical aims to expand the market size by further expanding the clinical indications of the WIRION system.
Customers
growth-positive
Allium Medical's System Receives FDA Approval
Medical equipment company Allium Medical has received approval from the US FDA to market Gardia Medicals WIRION EPD system. The system helps identify possible catheterization in the arteries that bring blood to the brain. This approval is a positive growth factor for Allium Medical.
Partners
growth-positive
Israel's Allium Medical Gets FDA Clearance for New Heart Surgery System
Israel-based medical device company Allium Medical has filed an application with the FDA for clearance of its WIRION filter system. The system is designed to prevent complications that can arise from cardiovascular operations, specifically protecting from emboli released during catheterization procedures. The application was submitted based on interim clinical data, with the company continuing to enroll additional patients in the clinical study. Alliums CEO, Asaf Alperovitz, expressed confidence in the likelihood of successfully meeting the studys primary end-point for a full cohort of 240 patients.
Customers
Employee Info
| Employees (range) | 11-50 |
| Exact count | 23 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
Allmed Solutions Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 97/100 |
| Missing | founding month, markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 513488833 |
| Crunchbase | allium-medical |
| Phone | +97246277166 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-01-15T00:00:00.000Z |
| Created | 2014-07-16T00:00:00.000Z |
| Status detail | Public on TASE on Feb, 2007; |